Subscribe
Daily Intelligence for Biotech Investors

The deal tapeserious biotech investors actually read

Top news, M&A, BD&L, IPOs, and VC financings — distilled to a 5-minute read every market morning. No hype. No filler. Just the signal.

Trusted by 2,000+ biotech execs, VCs, BD leads, public market investors - free
Latest Editions
Daily
Jun 17
Wednesday: Moderna's flu do-over, and the AI-deal machine hums
Moderna faces the FDA panel, Lilly grabs more pain, and Merck writes another AI check.
Jun 16
Tuesday: CRISPR's one-shot moment, Neumora's three-strike out
Intellia rewrites HAE, Spyre stokes TL1A takeout math, and Neumora cuts a third of staff.
Jun 15
Monday: J&J's Talvey posts a 72% myeloma edge
J&J leads on Phase 3 myeloma, Sanofi expands Tzield, and Lilly adds a CLL win as biotech stays bid.
Jun 12
Friday: Novo's pill era expansion; Takeda mugs BMS in broad daylight
Takeda bodies Sotyktu in a head-to-head, Penumbra gets its stroke green light, and Stockholm keeps the EHA data spigot open.
Jun 11
Thursday: Parabilis didn't get the red-tape memo
Hot CPI and an oil-fueled risk-off dragged biotech down with the tape — even a record IPO and a Phase 3 win couldn't keep the screen green.
2,000+
Subscribers
5×
Issues per week
16+
Research reports
$123.0B
M&A tracked YTD
Research Hub
Live trackers & research
View all →
Live Trackers
Live Tracker
Biotech M&A Tracker 2026
Every control transaction in 2026 — target, acquirer, deal value, premium-to-unaffected, and investor-grade rationale. 43 deals. $123.0B tracked.
Last updated 14 June 2026
Live Tracker
Biotech BD&L Tracker 2026
Licensing and partnering deals — upfronts, milestones, royalties, territory rights, and a one-line why it matters. 71 deals. Up to US$18.5B largest package.
Last updated 14 June 2026
Live Tracker
Biotech IPO Tracker 2026
Every biotech IPO this year — pricing date, proceeds, valuation at pricing, and aftermarket performance. 13 deals. ~$4.7B tracked.
Last updated 14 June 2026
Live Tracker
Biotech Venture Funding Tracker 2026
VC and crossover rounds — company, stage, lead investors, therapeutic area, and what they are building. 102 deals. US$2.1B largest round.
Last updated 14 June 2026
Research
Report
Most Active Biotech Investors 2026
Ranked league table of the most active biotech and biopharma investors in 2026 by qualifying deal participation.
Reference
Biotech Conference Calendar 2026
Major biotech and biopharma conferences in 2026 across the US, UK, and EU, including investor events, scientific catalysts, and partnering meetings.
Report
Top 10 BioPharma M&A Deals of 2025
Ranked list of the 10 biggest biopharma and biotech acquisitions announced in 2025, with stage, therapeutic area, and investor-grade read-through.
Report
Biotech M&A Q1 2026 Report
16 deals, $44B in value, and what the deal tape signals about where strategic buyers are paying up.
Report
2024 Biopharma M&A: Every $1B+ Deal
The complete list of 2024 biopharma acquisitions worth $1B or more — public and private targets.
Reference
Biotech Funding Terms Glossary
Plain-English definitions of the deal terms that appear in press releases, term sheets, IPOs, and M&A announcements.
About BioBucks

BioBucks is a daily newsletter for biotech and biopharma investors — covering M&A, BD&L deals, IPOs, venture rounds, and catalyst-driven market moves, with the framing that institutional dealmakers actually care about.

Every edition is written to be read in under 5 minutes, with the why it matters front and centre. No press release regurgitation. No noise.

Alongside the daily tape, the Research Hub provides live trackers and standalone reports that serve as reference tools for the community.

Who reads BioBucks
VC / GrowthBiotech venture investors tracking the deal environment
BD&LBusiness development professionals monitoring partnerships
Public MarketsBuyside analysts and portfolio managers
FoundersBiotech CEOs watching comps and M&A premiums